forum comments

OBR Daily Commentary

U.S. Medicare Sets Outpatient Rate For Yescarta Reimbursement

(Reuters) Apr 5, 2018 - Medicare, the U.S. government healthcare program for the elderly and disabled, will pay hospitals close to its standard mark-up rate for administering cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly $80,000, according to the Centers for Medicare & Medicaid Services (CMS).

Read Article

Winston Wong, PharmD (Posted: April 09, 2018)

CMS has set the reimbursement for their near normal outpatient rate, thus CMS is treating the CAR-T therapies as an outlier, since the normal hospital reimbursement would be based upon the DRG. Given the co-pay cap, there seems to be little margin for the institution. Need to watch can see what will happen with the additional service reimbursement request.

Add Comment 1 Comment(s)

Meet the Editorial Board

Prostate Cancer

Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

OBR Daily Commentary

U.S. Medicare Sets Outpatient Rate For Yescarta Reimbursement

Meet the Editorial Board

Prostate Cancer

Tomasz M. Beer, MD, FACP

Community Oncology

Dean Gesme, MD

Breast Cancer

Debu Tripathy, MD

Lung Cancer

H. Jack West, MD

Gastrointestinal Cancers

Howard S. Hochster, MD

Radiation Oncology

Howard Sandler, MD, MS, FASTRO

Community Oncology

Jeff Patton, M.D.

Precision Medicine Section Editor

Jennifer Levin Carter, MD, MPH

Financial Sector

Michael G. King Jr.

Gastrointestinal Cancers

Richard Goldberg, MD

Editor-In-Chief

Robert A. Figlin, MD., FACP

Health Policy

Ted Okon

Community Oncology

Thomas Marsland, MD

Community Oncology

William Harwin MD

Health Policy

William McGivney, PhD

Payer

Winston Wong, PharmD